Firefly Neuroscience Partners with Heidelberg University Hospital for Neuroscience Research Using FDA-Cleared BNA Platform

Firefly Neuroscience has signed a commercial agreement with Heidelberg University Hospital to use its FDA-cleared Brain Network Analytics platform in neuroscience research. The study, scheduled to run through 2026, aims to analyze EEG data and uncover novel insights into brain function in rare genetic conditions. Firefly's mission is to deepen understanding of cognitive disorders and transform diagnosis, monitoring, and treatment.

Firefly Neuroscience, Inc. (NASDAQ: AIFF), a neurotechnology company, has signed a commercial agreement with the Institute of Human Genetics at Heidelberg University Hospital to utilize its FDA-cleared Brain Network Analytics (BNA) platform in a neuroscience research study. The study, scheduled to run through 2026, aims to analyze electroencephalogram (EEG) data and uncover novel insights into brain function in rare genetic conditions.

The research, led by Prof. Dr. Christian Schaaf, will analyze EEG data from 30 subjects with genetic variations in the 15q13.3 chromosomal region. The study employs Firefly’s BNA technology to process resting state and cognitive paradigm data [1].

Scheduled to run through 2026, the study aims to identify electrophysiological biomarkers associated with these genetic variants and characterize neurocognitive profiles linked to deletions versus duplications of the chromosomal region. The collaboration builds on previous work between Firefly and Prof. Schaaf, including a joint publication on CHRNA7-related phenotypes [2].

Firefly is providing EEG systems, training, and analytical support for the project, including comparison to its proprietary normative database. The study aims to support future diagnostic and therapeutic strategies for neurodevelopmental disorders. "By combining Heidelberg’s clinical expertise with our proprietary technology, we aim to uncover novel insights into the brain’s functional architecture in rare genetic conditions," said Gil Issachar, Chief Technology Officer of Firefly [1].

This collaboration reflects Firefly's broader mission to deepen understanding of cognitive disorders and transform diagnosis, monitoring, and treatment. The company's BNA technology is designed to enhance clinicians’ ability to diagnose mental and cognitive disorders and evaluate treatment efficacy [1].

The study is part of Firefly's strategy to build and grow a license business, which is increasingly important in the commercial strategy of the company. Firefly's advancements in brain health technology are aimed at pharmaceutical companies and medical practitioners, and the company is poised for rapid growth and innovation [2].

References:
[1] https://www.investing.com/news/company-news/firefly-neuroscience-partners-with-heidelberg-on-rare-genetic-study-93CH-4133627
[2] https://finance.yahoo.com/news/firefly-inks-latest-commercial-agreement-114500578.html